Heart failure & cardiomyopathies
Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial
Authors' conclusion
In patients with HFpEF and obesity, semaglutide produced large improvements in HF-related symptoms, physical limitations, exercise function, inflammation, body weight, and N-terminal pro-brain natriuretic peptide, regardless of baseline health status. The benefits of semaglutide extended to all key KCCQ domains.
Study context
- Population
- Symptomatic heart failure (HF), EF ≥45% and BMI ≥30 kg/m², stratified by baseline KCCQ-CSS tertiles
- Participants
- 529 participants
- Comparison
- Semaglutide 2.4 mg once weekly vs placebo
- Primary endpoint
- Dual primary end points: change in KCCQ-CSS and body weight, across baseline KCCQ-CSS tertiles
- Follow-up
- 52 weeks
Methodological detailsprespecified analysis
- Prespecified analysis
Primary result
As reported in the abstract
Change in KCCQ-CSS and body weight by baseline KCCQ-CSS tertile (baseline median 37, 59, 77 points)
Semaglutide vs PlaceboEstimated treatment difference, points (95% CI)
KCCQ-CSS, tertile 1
10.7(5.4–16.1)
KCCQ-CSS, tertile 2
8.1(2.7–13.4)
KCCQ-CSS, tertile 3
4.6(−0.6 to 9.9)
Semaglutide vs PlaceboEstimated treatment difference (95% CI)
Body weight, tertile 1
−11(−13.2 to −8.8)
Body weight, tertile 2
−9.4(−11.5 to −7.2)
Body weight, tertile 3
−11.8(−14.0 to −9.6)
Secondary outcomes
Confirmatory secondary and exploratory end points (6-minute walk distance, hierarchical composite, CRP, NT-proBNP) across tertiles
- Consistent effects across KCCQ-CSS tertiles
- P for interaction > 0.1 for all
All key Kansas City Cardiomyopathy Questionnaire (KCCQ) domains
- Estimated treatment differences across domains
- 6.7-9.6 points; P≤0.001 for all
≥5-, 10-, 15- and 20-point improvement in all KCCQ domains
- Greater proportion with semaglutide vs placebo; ORs across domains
- 1.6-2.9; P<0.05 for all
Original publication
Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. Circulation. Published 12 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →